FDA Alerts

FDA approves therapy for adult growth hormone deficiency

The US Food and Drug Administration (FDA) has approved somapacitan (Sogroya) for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD), according to a press release. This is the first human growth hormone (hGH) therapy taken weekly by injection. Approval was based off a randomized, double-blind,...